Clinical Research Directory

Inclusion Criteria: * Patients \>40 \<65 years of age * Diagnosis of AML in first complete remission (CR)/complete remission with incomplete recovery (CRi)/multiflow leukemia free state (MLFS) * Eligible for allo-SCT from HLA-identical matched related or unrelated donor as defined by molecular high-resolution typing (4 digits) at the following four HLA gene loci (HLA-A, B, C, and DRB1) * Adequate hepatic function (bilirubin ≤2 UNL; ALT/AST ≤2,5 UNL) * Adequate renal function (creatinine clearance ≥50 mL/min) * ECOG Performance Status \< 2 * Willing and able to comply with all of the requirements and visits in the protocol. * Written and signed informed consent Exclusion Criteria: * AML patients with t(15;17); t(8;21); inv(16) * Subject has known active CNS involvement with AML. * Grade \>2 NCI-CTCAE (v. 5) adverse events at the time of enrollment * Serious organ dysfunction: left ventricular ejection fraction \< 40%, FEV1, FVC, DLCO (diffusion capacity) \<40% of predicted, LFT \> 5 times the upper limit of normal, or creatinine clearance \< 40 ml/min. * The evidence of HBV or HCV active infection (HBV DNA, HCV RNA positive test). * Patients with HIV infection * Current uncontrolled infections * Patients with other life-threatening concurrent diseases * Subjects with known hypersensitivity to any of the component medications * Participation in another clinical trial within 1 month before the start of this trial * Participant, both female and male, in childbearing age who do not agree to maintain an active contraceptive practice * Pregnant or breastfeeding patients during screening